Opinion|Videos|December 11, 2024
Unresponsive NMIBC: Gene Therapies
Author(s)Katie S. Murray, DO, MS
Key Takeaways
- Targeted gene therapy personalizes treatment for BCG-unresponsive NMIBC, improving efficacy and minimizing systemic side effects by focusing on specific genetic mutations.
- Gene therapies that do not require specialized equipment, such as biosafety hoods, simplify administration and reduce logistical burdens on clinics.
Katie S. Murray, DO, discusses how the introduction of targeted gene therapies has shifted the approach to managing BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), offering more personalized treatment options, and explains how the ease of administration—without the need for specialized equipment like biosafety hoods—reduces logistical burdens on clinics.
Advertisement
Episodes in this series
- How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics?
Advertisement
Related to this article
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement
Trending on Urology Times
1
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5